Capricor Therapeutics, Inc.
Deramiocel
Duchenne muscular dystrophy
Countdown
23days
Advisory committee · Jul 29, 2026
What's at stake
An FDA advisory committee reviews Deramiocel for Duchenne muscular dystrophy around Jul 29, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy –Advisory Committee meeting scheduled for July 29, 2026–”